All Title Author
Keywords Abstract

PLOS ONE  2014 

Autophagy Inhibition Contributes to the Synergistic Interaction between EGCG and Doxorubicin to Kill the Hepatoma Hep3B Cells

DOI: 10.1371/journal.pone.0085771

Full-Text   Cite this paper   Add to My Lib


(-)-Epigallocatechin-3-O-gallate(EGCG), the highest catechins from green tea, has promisingly been found to sensitize the efficacy of several chemotherapy agents like doxorubicin (DOX) in hepatocellular carcinoma (HCC) treatment. However, the detailed mechanisms by which EGCG augments the chemotherapeutic efficacy remain unclear. Herein, this study was designed to determine the synergistic impacts of EGCG and DOX on hepatoma cells and particularly to reveal whether the autophagic flux is involved in this combination strategy for the HCC. Electron microscopy and fluorescent microscopy confirmed that DOX significantly increased autophagic vesicles in hepatoma Hep3B cells. Western blot and trypan blue assay showed that the increasing autophagy flux by DOX impaired about 45% of DOX-induced cell death in these cells. Conversely, both qRT-PCR and western blotting showed that EGCG played dose-dependently inhibitory role in autophagy signaling, and that markedly promoted cellular growth inhibition. Amazingly, the combined treatment caused a synergistic effect with 40 to 60% increment on cell death and about 45% augmentation on apoptosis versus monotherapy pattern. The DOX-induced autophagy was abolished by this combination therapy. Rapamycin, an autophagic agonist, substantially impaired the anticancer effect of either DOX or combination with EGCG treatment. On the other hand, using small interference RNA targeting chloroquine autophagy-related gene Atg5 and beclin1 to inhibit autophagy signal, hepatoma cell death was dramatically enhanced. Furthermore, in the established subcutaneous Hep3B cells xenograft tumor model, about 25% reduction in tumor growth as well as 50% increment of apoptotic cells were found in combination therapy compared with DOX alone. In addition, immunohistochemistry analysis indicated that the suppressed tendency of autophagic hallmark microtubule-associated protein light chain 3 (LC3) expressions was consistent with thus combined usage in vitro. Taken together, the current study suggested that EGCG emerges as a chemotherapeutic augmenter and synergistically enhances DOX anticancer effects involving autophagy inhibition in HCC.


[1]  Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42 Suppl 3S206–214.
[2]  Maluccio M, Covey A (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62: 394–399.
[3]  Gluer AM, Cocco N, Laurence JM, Johnston ES, Hollands MJ, et al. (2012) Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford) 14: 285–290.
[4]  Lin S, Hoffmann K, Xiao Z, Jin N, Galli U, et al. (2013) MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell Int 13: 3.
[5]  Sul YH, Lee MS, Cha EY, Thuong PT, Khoi NM, et al. (2013) An ent-Kaurane Diterpenoid from Croton tonkinensis Induces Apoptosis by Regulating AMP-Activated Protein Kinase in SK-HEP1 Human Hepatocellular Carcinoma Cells. Biol Pharm Bull 36: 158–164.
[6]  Cao H, Phan H, Yang LX (2012) Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 32: 1379–1386.
[7]  Liang G, Tang A, Lin X, Li L, Zhang S, et al. (2010) Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int J Oncol 37: 111–123.
[8]  Bhutia SK, Mukhopadhyay S, Sinha N, Das DN, Panda PK, et al. (2013) Autophagy: cancer's friend or foe? Adv Cancer Res 118: 61–95.
[9]  Zhang G, Park MA, Mitchell C, Walker T, Hamed H, et al. (2008) Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. J Biol Chem 283: 24343–24358.
[10]  He W, Wang Q, Srinivasan B, Xu J, Padilla MT, et al.. (2013) A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene.
[11]  Lee AJ, Roylance R, Sander J, Gorman P, Endesfelder D, et al. (2012) CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J Pathol 226: 482–494.
[12]  Zhu L, Du H, Shi M, Chen Z, Hang J (2013) ATG7 deficiency promote apoptotic death induced by Cisplatin in human esophageal squamous cell carcinoma cells. Bull Cancer.
[13]  Kang R, Tang D (2012) Autophagy in pancreatic cancer pathogenesis and treatment. Am J Cancer Res 2: 383–396.
[14]  Xie BS, Zhao HC, Yao SK, Zhuo DX, Jin B, et al. (2011) Autophagy inhibition enhances etoposide-induced cell death in human hepatoma G2 cells. Int J Mol Med 27: 599–606.
[15]  Selvakumaran M, Amaravadi RK, Vasilevskaya IA, O'Dwyer PJ (2013) Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin Cancer Res 19: 2995–3007.
[16]  Choi JH, Yoon JS, Won YW, Park BB, Lee YY (2012) Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration. APMIS 120: 597–604.
[17]  Xu N, Zhang J, Shen C, Luo Y, Xia L, et al. (2012) Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 423: 826–831.
[18]  Humbert M, Medova M, Aebersold DM, Blaukat A, Bladt F, et al. (2013) Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochem Biophys Res Commun 431: 264–269.
[19]  Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, et al. (2011) Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 7: 1159–1172.
[20]  Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, et al. (2012) Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 131: 548–557.
[21]  Kuo PL, Lin CC (2003) Green tea constituent (-)-epigallocatechin-3-gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. J Biomed Sci 10: 219–227.
[22]  Tu SH, Ku CY, Ho CT, Chen CS, Huang CS, et al. (2011) Tea polyphenol (-)-epigallocatechin-3-gallate inhibits nicotine- and estrogen-induced alpha9-nicotinic acetylcholine receptor upregulation in human breast cancer cells. Mol Nutr Food Res 55: 455–466.
[23]  Hashimoto K, Sakagami H (2008) Induction of apoptosis by epigallocatechin gallate and autophagy inhibitors in a mouse macrophage-like cell line. Anticancer Res 28: 1713–1718.
[24]  Li W, Zhu S, Li J, Assa A, Jundoria A, et al. (2011) EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem Pharmacol 81: 1152–1163.
[25]  Yan J, Feng Z, Liu J, Shen W, Wang Y, et al. (2012) Enhanced autophagy plays a cardinal role in mitochondrial dysfunction in type 2 diabetic Goto-Kakizaki (GK) rats: ameliorating effects of (-)-epigallocatechin-3-gallate. J Nutr Biochem 23: 716–724.
[26]  Zhang Y, Yang ND, Zhou F, Shen T, Duan T, et al. (2012) (-)-Epigallocatechin-3-gallate induces non-apoptotic cell death in human cancer cells via ROS-mediated lysosomal membrane permeabilization. PLoS One 7: e46749.
[27]  Gong H, Zhang X, Cheng B, Sun Y, Li C, et al. (2013) Bisphenol A accelerates toxic amyloid formation of human islet amyloid polypeptide: a possible link between bisphenol A exposure and type 2 diabetes. PLoS One 8: e54198.
[28]  Wang D, Wang Z, Tian B, Li X, Li S, et al. (2008) Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int J Urol 15: 435–441.
[29]  Mizushima N, Yoshimori T, Levine B (2010) Methods in Mammalian Autophagy Research. Cell.
[30]  Manov I, Pollak Y, Broneshter R, Iancu TC (2011) Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib–the role of extracellular signal-regulated kinase counteraction. FEBS J 278: 3494–3507.
[31]  Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, et al. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710–717.
[32]  Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125: 47–58.
[33]  Nobili S, Landini I, Giglioni B, Mini E (2006) Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7: 861–879.
[34]  Szeto J, Kaniuk NA, Canadien V, Nisman R, Mizushima N, et al. (2006) ALIS are stress-induced protein storage compartments for substrates of the proteasome and autophagy. Autophagy 2: 189–199.
[35]  Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, et al. (2013) Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemother Pharmacol 71: 1567–1576.
[36]  Han W, Sun J, Feng L, Wang K, Li D, et al. (2011) Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS One 6: e28491.
[37]  Liu F, Liu D, Yang Y, Zhao S (2013) Effect of autophagy inhibition on chemotherapy-induced apoptosis in A549 lung cancer cells. Oncol Lett 5: 1261–1265.
[38]  Pan Y, Gao Y, Chen L, Gao G, Dong H, et al. (2011) Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res 17: 3248–3258.
[39]  Carew JS, Kelly KR, Nawrocki ST (2012) Autophagy as a target for cancer therapy: new developments. Cancer Manag Res 4: 357–365.
[40]  Stelton CR, Connors DB, Walia SS, Walia HS (2013) Hydrochloroquine retinopathy: characteristic presentation with review of screening. Clin Rheumatol 32: 895–898.
[41]  Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, et al. (2006) (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 66: 9260–9269.
[42]  Chen TC, Wang W, Golden EB, Thomas S, Sivakumar W, et al. (2011) Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett 302: 100–108.
[43]  Abbas S, Wink M (2010) Epigallocatechin gallate inhibits beta amyloid oligomerization in Caenorhabditis elegans and affects the daf-2/insulin-like signaling pathway. Phytomedicine 17: 902–909.
[44]  Zheng J, Lee HC, Bin Sattar MM, Huang Y, Bian JS (2011) Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury. Eur J Pharmacol 652: 82–88.
[45]  Xu X, Chen K, Kobayashi S, Timm D, Liang Q (2012) Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J Pharmacol Exp Ther 341: 183–195.
[46]  Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S, et al. (2008) Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 167: 71–77.
[47]  Schramm L (2013) Going Green: The Role of the Green Tea Component EGCG in Chemoprevention. J Carcinog Mutagen 4: 1000142.
[48]  Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, et al. (2008) Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev 17: 3020–3025.
[49]  Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, et al. (2009) Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2: 931–941.


comments powered by Disqus